ICER says Pfizer’s Paxlovid, Merck’s molnupiravir both cost effective, but their benefits are far from equal

ICER says Pfizer’s Paxlovid, Merck’s molnupiravir both cost effective, but their benefits are far from equal
fkansteiner
Tue, 05/10/2022 – 09:00
Click here to view original post